Stockreport

Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer

Enzo Biochem, Inc. ($0.01 Par Value)  (ENZ) 
Last enzo biochem, inc. ($0.01 par value) earnings: 12/7 04:10 pm Check Earnings Report
US:NYSE Investor Relations: enzo.com/corporate/investor-information
PDF Drug Candidate SK1-I Shown to Reverse Tamoxifen Resistance in Human Breast Cancer Preclinical Study NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, [Read more]